journal article·2023-12Open access

An Aggregation‐Induced Emission Molecule‐Assembled Nanovaccine with Self‐Adjuvanted Function for Cancer Immunotherapy

Xiaoyan Zhang, Kefei Wang, Zhiyuan Gao, Zelin Wu, Wei Liu, Jisen Li, Heqi Gao, Jun Wei, Dan Ding, Wenting Zheng

Advanced Functional Materials· Volume 33· Issue 51

Abstract

Abstract Cancer nanovaccine is a promising therapeutic strategy; however, the complicated composition and ambiguous structure of cancer nanovaccines hinder their clinical application. Thus, developing minimalist nanovaccine with simple structural molecule and potent immunostimulatory function is with great value. Herein, an organic small molecule with well‐defined molecular structure and strong aggregation‐induced emission (AIE) activity is synthesized. This molecule can self‐assemble into nanoparticle (NM‐7) acting as not only adjuvant but also carrier to capture model antigen ovalbumin to form nanovaccine, which can effectively deliver and chronically release antigens and induce effective antigen cross‐presentation in draining lymph nodes. Additionally, the photophysical property of AIE molecule facilitates the determination of in vivo tissue distribution of NM‐7. Notably, NM‐7/ovalbumin (OVA) nanovaccine induces robust tumor‐specific CD8+ T‐cell responses with greatly reduced cell exhaustion. Accordingly, NM‐7/OVA nanovaccine shows potent efficacy in both prevention and therapeutic tumor models, and produces an impressive synergistic therapeutic effect when combined with immune checkpoint blockade (ICB) therapy. Therefore, AIE nanomaterial NM‐7 with simple synthesis, well‐defined molecular structure and self‐adjuvanted function provides a new reference and general strategy for cancer vaccine development.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Stomatological Hospital School of Medicine Nankai University Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction State Key Laboratory of Experimental Hematology Tianjin 300041 China

Frontiers Science Center for Cell Responses State Key Laboratory of Medicinal Chemical Biology Key Laboratory of Bioactive Materials Ministry of Education College of Life Sciences Nankai University Tianjin 300071 China

State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300020 China

References (64)

Show source-provided references
1. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
2. 10.1126/science.342.6165.143210.1126/science.342.6165.1432 ↗
3. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
4. 10.1186/s13045-021-01164-510.1186/s13045-021-01164-5 ↗
5. 10.1158/2326-6066.CIR-18-027710.1158/2326-6066.CIR-18-0277 ↗
6. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
7. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
8. 10.3390/vaccines402001210.3390/vaccines4020012 ↗
9. 10.1002/adma.20220216810.1002/adma.202202168 ↗
10. 10.1016/j.addr.2021.11396610.1016/j.addr.2021.113966 ↗
11. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
12. 10.1021/acs.nanolett.0c0123010.1021/acs.nanolett.0c01230 ↗
13. 10.1002/ange.20200611710.1002/ange.202006117 ↗
14. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
15. 10.1002/adma.20210925410.1002/adma.202109254 ↗
16. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
17. 10.1186/s12951-022-01545-z10.1186/s12951-022-01545-z ↗
18. 10.1021/acs.chemrev.5b0014010.1021/acs.chemrev.5b00140 ↗
19. 10.1039/C8CS00001H10.1039/C8CS00001H ↗
20. 10.1002/adma.20180633110.1002/adma.201806331 ↗
21. 10.1016/j.addr.2021.11402810.1016/j.addr.2021.114028 ↗
22. 10.1021/acs.chemrev.5b0026310.1021/acs.chemrev.5b00263 ↗
23. 10.1002/adma.20170685610.1002/adma.201706856 ↗
24. 10.1002/adfm.20110219110.1002/adfm.201102191 ↗
25. 10.2217/nnm-2018-014710.2217/nnm-2018-0147 ↗
26. 10.1021/acs.accounts.2c0036010.1021/acs.accounts.2c00360 ↗
27. 10.1021/cm061594t10.1021/cm061594t ↗
28. 10.1080/14756366.2018.151392510.1080/14756366.2018.1513925 ↗
29. 10.1007/s11426-013-4924-710.1007/s11426-013-4924-7 ↗
30. 10.1002/smll.20120250510.1002/smll.201202505 ↗
31. 10.1002/adma.20190491410.1002/adma.201904914 ↗
32. 10.1002/adma.20170440810.1002/adma.201704408 ↗
33. 10.1016/j.jconrel.2020.11.05610.1016/j.jconrel.2020.11.056 ↗
34. 10.1021/acs.molpharmaceut.9b0086010.1021/acs.molpharmaceut.9b00860 ↗
35. 10.1038/nri184510.1038/nri1845 ↗
36. 10.1016/j.addr.2021.11391410.1016/j.addr.2021.113914 ↗
37. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
38. 10.1038/nri286810.1038/nri2868 ↗
39. 10.1007/s11095-022-03301-210.1007/s11095-022-03301-2 ↗
40. 10.1038/nri330710.1038/nri3307 ↗
41. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗
42. 10.1002/anie.20200084510.1002/anie.202000845 ↗
43. 10.1039/c3tc30759j10.1039/c3tc30759j ↗
44. 10.1021/acsmaterialslett.0c0051610.1021/acsmaterialslett.0c00516 ↗
45. 10.1039/C5TC01159K10.1039/C5TC01159K ↗
46. 10.1002/adma.20170390010.1002/adma.201703900 ↗
47. 10.1038/nri325410.1038/nri3254 ↗
48. 10.1016/S0092-8674(01)00455-X10.1016/S0092-8674(01)00455-X ↗
49. 10.1172/JCI8108310.1172/JCI81083 ↗
50. 10.1038/ncomms1332410.1038/ncomms13324 ↗
51. 10.1038/nature1297810.1038/nature12978 ↗
52. 10.1038/s41578-021-00372-210.1038/s41578-021-00372-2 ↗
53. 10.1073/pnas.171821711510.1073/pnas.1718217115 ↗
54. 10.1016/j.it.2004.12.00610.1016/j.it.2004.12.006 ↗
55. 10.1038/s41577-019-0221-910.1038/s41577-019-0221-9 ↗
56. 10.1016/j.immuni.2007.09.00610.1016/j.immuni.2007.09.006 ↗
57. 10.1038/s41589-018-0161-x10.1038/s41589-018-0161-x ↗
58. 10.1016/j.vaccine.2015.10.13210.1016/j.vaccine.2015.10.132 ↗
59. 10.1002/adma.20210925410.1002/adma.202109254 ↗
60. 10.1111/irv.1269710.1111/irv.12697 ↗
61. 10.1126/sciadv.aaw607110.1126/sciadv.aaw6071 ↗
62. 10.1002/adma.20190125510.1002/adma.201901255 ↗
63. 10.1002/adhm.20200084510.1002/adhm.202000845 ↗
64. 10.1038/s41586-021-04243-210.1038/s41586-021-04243-2 ↗